Biotechnology firm Moderna is celebrating after “tremendously exciting” preliminary results from late-stage trials of its Covid-19 vaccine, says Sarah Knapton in The Daily Telegraph. So far, only five people in the trial who received the jab have contracted the virus, compared with 90 who received a placebo, implying that it is nearly 95%-effective in preventing infection. That would make it “even more effective than either the Pfizer/BioNTech or Russian jab”. The trials suggest that it can even protect “the elderly and vulnerable who are most at risk”, with no one who has received the jab developing severe Covid-19 yet (compared with 11 from the placebo group).
Moderna’s success is “stunning”, says Robert Cyran on Breakingviews. Not only is it highly effective, but side effects are also “moderate”. More importantly, it can be stored in a conventional freezer for six months, and in a fridge up to 30 days, making it much easier to distribute than Pfizer’s vaccine, which must be “kept far colder, complicating distribution”. This is particularly good news for emerging markets, who not only lack expensive storage facilities, but will also benefit from the fact that richer countries have ordered far more doses than they need. The US alone ordered 600 million doses.
Vindication after a volatile year
This is “great news”, says Lex in the Financial Times. The data also brings “vindication for one of the sector’s most divisive companies”. After a “record-setting” initial public offering in December 2018, its shares spent much of 2019 trading below its opening price. However, the coronavirus pandemic has put its work on messenger-RNA, which prompts the body to make its own medicine, “back into focus”. Indeed, there are hopes that the Covid-19 jab may represent “proof of concept” for other Moderna treatments, including a personalised cancer vaccine. So, it’s no surprise that its shares have risen by 390% this year. Thanks to its latest success, Moderna should easily find enough money to develop its other vaccines, says Charley Grant in The Wall Street Journal. Its $40bn valuation means it can raise funds by selling shares and it also has $4bn in cash on the books. Selling even 500 million doses of vaccine at $200 each would translate into $10bn, which should come with “attractive profit margins” as Moderna’s decision not to seek a partner means that “it won’t have to share those profits”.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
AstraZeneca should also be happy, says Nils Pratley in the Guardian. Moderna’s trial suggests that its own jab, developed in conjunction with Oxford University, will report similarly good news next month. What’s more, it stands to benefit from the fact that it “made a very good bet” when it invested in Moderna as long ago as 2013, back when it was a “three-year-old biotechnology tiddler”. As a result, its 7.6% stake, which cost just $380m, is now worth $2.9bn – a “very decent” return.
-
UK inflation slowed again in March – but a rate cut could be some months awayThe latest Consumer Price Index (CPI) data came in at 3.2% for March, taking us closer to the Bank of England’s 2% inflation target.
-
Pension vs property: which option provides the best income for your retirement?News With the cost of a comfortable retirement on the rise, future retirees need to weigh up which strategy offers the best returns. But is a pension a better bet than property?
-
The industry at the heart of global technologyThe semiconductor industry powers key trends such as artificial intelligence, says Rupert Hargreaves
-
Three emerging Asian markets to invest inProfessional investor Chetan Sehgal of Templeton Emerging Markets Investment Trust tells us where he’d put his money
-
What to consider before investing in small-cap indexesSmall-cap index trackers show why your choice of benchmark can make a large difference to long-term returns
-
Why space investments are the way to go for investorsSpace investments will change our world beyond recognition, UK investors should take note
-
Time to tap into Africa’s mobile money boomFavourable demographics have put Africa on the path to growth when it comes to mobile money and digital banking
-
M&S is back in fashion: but how long can this success last?M&S has exceeded expectations in the past few years, but can it keep up the momentum?
-
The end of China’s boomLike the US, China too got fat on fake money. Now, China's doom is not far away.
-
Magic mushrooms — an investment boom or doom?Investing in these promising medical developments might see you embark on the trip of a lifetime.
